Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study.

Garrel R, Mazel M, Perriard F, Vinches M, Cayrefourcq L, Guigay J, Digue L, Aubry K, Alfonsi M, Delord JP, Lallemant B, Even C, Daurès JP, Landais P, Cupissol D, Alix-Panabières C.

Clin Chem. 2019 Oct;65(10):1267-1275. doi: 10.1373/clinchem.2019.305904. Epub 2019 Aug 6.

PMID:
31387885
2.

The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials.

Fortpied C, Vinches M.

Front Oncol. 2019 Jul 12;9:634. doi: 10.3389/fonc.2019.00634. eCollection 2019. Review.

3.

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.

Viala M, Vinches M, Alexandre M, Mollevi C, Durigova A, Hayaoui N, Homicsko K, Cuenant A, Gongora C, Gianni L, Tosi D.

Br J Cancer. 2018 Mar 6;118(5):679-697. doi: 10.1038/bjc.2017.473. Epub 2018 Feb 13.

4.

Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.

Tosi D, Laghzali Y, Vinches M, Alexandre M, Homicsko K, Fasolo A, Del Conte G, Durigova A, Hayaoui N, Gourgou S, Gianni L, Mollevi C.

J Clin Oncol. 2015 Jul 1;33(19):2158-65. doi: 10.1200/JCO.2014.58.1082. Epub 2015 May 26. Review.

PMID:
26014300

Supplemental Content

Loading ...
Support Center